A photo of Bradley Keller.

Co-Director, Greater Louisville and Western KY Practice, Heart Institute

Professor, UC Department of Pediatrics

502-584-3200

Board Certified

My Biography & Research

Biography

Dr. Keller is a clinician-investigator who provides care to children and adults with congenital heart disease throughout Kentucky. He is also an expert in the causes of congenital heart disease and in the development and testing of novel technologies for children and adults with heart disease. On March 1, 2020, Dr. Brad Keller joined the Cincinnati Children's Heart Institute and Dr. Juan Villafañe, as co-director of Cincinnati Children’s Heart Institute – Greater Louisville and Western Kentucky practices, and is at our offices throughout the region. He brings more than 30 years of clinical and administrative congenital heart care experience including prior roles as division chief of Pediatric Cardiology at the University of Kentucky and at the Children’s Hospital of Pittsburgh.

Clinical Interests

Pediatric and adult congenital heart disease

Research Interests

Clinical translation of outpatient telemedicine

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Adolescent and Adult Congenital Heart Disease, Heart Institute, Cardiology Clinic

Research Divisions

Heart Institute

My Locations

My Education

Pediatric Cardiology Fellowship: University of Rochester Medical Center, Rochester, NY, 1988-1991.

Pediatric Residency: Johns Hopkins Hospital, Baltimore, MD, 1985-1988.

MD: Pennsylvania State University School of Medicine, Hershey, PA, 1981-1985.

BS: University of Pennsylvania, Philadelphia, PA, 1977-1981.

My Publications

Zinc as a countermeasure for cadmium toxicity. Yu, H; Zhen, J; Leng, J; Cai, L; Ji, H; Keller, BB. Acta Pharmacologica Sinica. 2021; 42:340-346.

Emerging roles of microRNA-208a in cardiology and reverse cardio-oncology. Wang, X; Chen, X; Xu, H; Zhou, S; Zheng, Y; Keller, BB; Cai, L. Medicinal Research Reviews. 2021.

Better outcomes in pulmonary arterial hypertension after repair of congenital heart disease compared with idiopathic pulmonary arterial hypertension. Xu, Z; Gatzoulis, MA; Dimopoulos, K; Li, Q; Zhang, C; Keller, BB; Gu, H. 2021.

Successful outcomes for atrial septal defect associated with pulmonary arterial hypertension using a “treat-repair-treat” strategy. He, Y; Li, Q; Zhang, C; Keller, BB; Gu, H. 2021; 2.

Chronic Optogenetic Pacing of Human-Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissues. Dwenger, M; Kowalski, WJ; Masumoto, H; Nakane, T; Keller, BB. Methods in Molecular Biology. 2021; 2191:151-169.

Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy. Wang, X; Chen, XX; Yu, HT; Tan, Y; Lin, Q; Keller, BB; Zheng, Y; Cai, L. Acta Pharmacologica Sinica. 2020.

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Tan, Y; Zhang, Z; Zheng, C; Wintergerst, KA; Keller, BB; Cai, L. Nature Reviews Cardiology. 2020; 17:585-607.

Validating the Paradigm That Biomechanical Forces Regulate Embryonic Cardiovascular Morphogenesis and Are Fundamental in the Etiology of Congenital Heart Disease. Keller, BB; Kowalski, WJ; Tinney, JP; Tobita, K; Hu, N. Journal of Cardiovascular Development and Disease. 2020; 7.

Preparation of Mesh-Shaped Engineered Cardiac Tissues Derived from Human iPS Cells for In Vivo Myocardial Repair. Nakane, T; Abulaiti, M; Sasaki, Y; Kowalski, WJ; Keller, BB; Masumoto, H. Journal of Visualized Experiments. 2020.

Zinc protects against cadmium-induced toxicity in neonatal murine engineered cardiac tissues via metallothionein-dependent and independent mechanisms. Yu, H; Zhen, J; Xu, J; Cai, L; Leng, J; Ji, H; Keller, BB. Acta Pharmacologica Sinica. 2020; 41:638-649.